Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the compensation committee of the company's board of directors granted twenty new employees options to purchase a total of 310,500 shares of the company's common stock at an exercise price per share of $29.93, which was the closing price on december 8, 2020. the stock options were granted pursuant to the compa
RCUS Ratings Summary
RCUS Quant Ranking